Teva präsentiert neue Analysen zur Wirksamkeit und Sicherheit von Fremanezumab bei erwachsenen Patienten mit schwer behandelbarer Migräne auf dem 19. Kongress der International Headache Society - Seite 2

Nachstehend eine Auswahl der angenommenen Abstracts, die auf der IHC 2019 präsentiert werden:

Brandaktuelle Daten:

• [IHC-LB-006] Burden of comorbid depression and anxiety on migraine-specific health-related quality of life in adult migraine patients in the United States (6. September 2019, 11 – 12 Uhr IST)
• [IHC-LB-030] 10-year cost-effectiveness analyses of response-based fremanezumab use in migraine patients with inadequate response to prior preventive treatments (6. September 2019, 11 – 12 Uhr IST)
• [IHC-LB-037] 10-year cost-effectiveness analyses of fremanezumab compared to erenumab as preventive treatment in episodic migraine for patients with inadequate response to prior preventive treatments (6. September 2019, 11 – 12 Uhr IST)
• [IHC-OR-040] (de novo): Efficacy and safety of fremanezumab for the prevention of episodic cluster headache: results of a randomized, double-blind, placebo-controlled, phase 3 study (8. September 2019, 8:20 Uhr IST)

Mündlicher Vortrag:

• [IHC-OR-012] Very early onset* of action of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study (7. September 2019, 10:30 Uhr IST)

Posterpräsentationen:

• [IHC-PO-138] Efficacy with fremanezumab in migraine patients with comorbid moderate to severe depression and documented inadequate response to 2-4 classes of migraine preventive treatments: subgroup analysis of the randomised, placebo-controlled FOCUS study (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-137] Early onset* of response to fremanezumab in migraine patients with moderate to severe depression and documented inadequate response to 2-4 classes of migraine preventive treatments: subgroup analysis of the randomised, placebo-controlled FOCUS study (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-156] Efficacy of fremanezumab in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications: subgroup analysis of the randomised, placebo-controlled FOCUS study (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-148] Impact of fremanezumab on disability in migraine patients with medication overuse and documented inadequate response to 2-4 classes of preventive treatments: subgroup analysis of the randomised, double-blind FOCUS study (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-149] Impact of fremanezumab on migraine-specific quality of life in patients with medication overuse and documented inadequate response to 2-4 classes of migraine preventive treatments: subgroup analysis of the international, multicentre, randomised, double-blind FOCUS study (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-150] Early onset* of efficacy with fremanezumab in patients with medication overuse and documented inadequate response to 2-4 classes of migraine preventive treatments: subgroup analysis of the randomised, double-blind FOCUS study (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-157] Clinically meaningful responses to fremanezumab in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications in the randomised, placebo-controlled FOCUS study (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-171] A pharmacokinetic bioequivalence study of fremanezumab administered subcutaneously using an autoinjector and a prefilled syringe (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-172] Impact of fremanezumab on any acute headache medication use in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications in the multicentre, randomised, placebo-controlled FOCUS study (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-151] Reversion from chronic to episodic migraine in patients with documented inadequate response to 2-4 classes of migraine preventive treatments: results of the randomised, placebo-controlled FOCUS study (6. September 2019, 11 – 12 Uhr IST)
• [IHC-PO-384] Efficacy of fremanezumab in male patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the randomised, placebo-controlled FOCUS study (7. September 2019, 14:45 – 15:45 Uhr IST)
• [IHC-PO-404] Patient preference and satisfaction following completion of a 1-year extension study (7. September 2019, 14:45 – 15:45 Uhr IST)
• [IHC-PO-388] Functioning and productivity impact of fremanezumab in migraine patients: a patient survey study following completion of a 1-year extension study (7. September 2019, 14:45 – 15:45 Uhr IST)

*Early onset bzw. frühes Einsetzen der Wirksamkeit (Wirksamkeitsmesswerte: Reduzierung der Migränetage, Reduzierung der Kopfschmerztage, Ansprechrate) ist definiert als Woche Eins nach der Einleitung der Therapie.